The
global Antibody Drug Conjugate Market size is expected to
reach USD 9.93 billion by 2025, according to a new report by Grand View
Research, Inc. it is projected to expand at a CAGR of 25.9% over the forecast
period. Increasing incidence of cancer coupled with growing geriatric
population are likely to drive the market for Antibody-Drug Conjugates (ADC).
Furthermore, major technological advancements are also contributing to drive
the growth. According to the World Health Organization (WHO), the number of
people aged 65 years and above, is projected to reach 16% of the total
population by 2050 from 7% in 2000. Aging has become a substantial risk factor
for numerous diseases including cancer and others. Hence, the growing geriatric
population is expected to drive growth of the market over the forecast period.
Until
2018, four ADCs were available in the market, namely, Adcetris, Kadcyla,
Besponsa, and Mylotarg. Due to appropriate targeting and improved technology,
ADCs have been gaining a lot of attention from both small and large
pharmaceutical companies. Currently there are more than 50 ADCs in clinical
trials and it has been projected that during the forecast period three to four
ADCs will be commercialized in the area of refractory Hodgkin lymphoma,
glioblastoma, small cell lung cancer, breast cancer, and ovarian cancer. It has
been observed that the maximum number of clinical trials are being conducted for
lymphoma.
Seattle
Genetics and Roche are leading the antibody drug conjugate market in terms of
market share. Until 2017 only two ADCs were commercially available-Adcetris by
Seattle Genetics and Kadcyla by Roche. Recently, two more Pfizer’s products
were approved to be marketed for acute myeloid leukaemia and acute
lymphoblastic leukaemia. Hence, it has been estimated that over the forecast
period, Pfizer is anticipated to gain a significant market share.
Browse
Details of Report @ https://www.grandviewresearch.com/industry-analysis/antibody-drug-conjugates-market
Further key findings from the report suggest:
- Breast
cancer was the largest segment in 2017 and is likely to witness a
significant growth over the forecast period due to the factors such as
availability of Kadcyla and high prevalence of breast cancer
- Cleavable
linker is expected to witness the fastest growth over the forecast period
as the maximum product in the pipeline contains cleavable linkers. In
addition, in 2017 two new products-Besponsa and Mylotarg were approved in
the market
- In 2017,
North America was the largest revenue generating region in the
antibody-drug conjugates market. It is the most well-established regions
in terms of patient awareness and usage of ADCs and makes up most of the
existing market
- The players
operating in this space are F. Hoffmann-La Roche Ltd; Seattle Genetics,
Inc.; Pfizer Inc.; Takeda Pharmaceutical Company Limited; AbbVie Inc.;
Immunomedics; and ImmunoGen Inc.
- Market
players are adopting strategies, such as introducing technologically
advanced products, collaborations, and geographic expansions to increase
their market share. For instance, Seattle Genetics collaborated with
Takeda for developing brentuximab vedotin (Adcetris) for
refractory/relapsed Hodgkin lymphoma.
About Us:
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com
Blog: https://healthcareforecastreport.blogspot.com/
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com
Blog: https://healthcareforecastreport.blogspot.com/
No comments:
Post a Comment